Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,228,387 papers from all fields of science
Search
Sign In
Create Free Account
Hemodialysis Extraction Ratio
Known as:
HDER
The determination of the fractional content of a substance removed from the blood during a hemodialysis session.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
CDISC SDTM Pharmacokinetic Parameter Long Name Terminology
Clinical Data Interchange Standards Consortium Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
B. Bergmark
,
P. Kamphuisen
,
+8 authors
R. Giugliano
Circulation
2019
Corpus ID: 204029492
Background: Numerous scales exist for classification of major bleeding events. There are limited data comparing the most commonly…
Expand
2018
2018
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation: A Nationwide Cohort Study
H. Yu
,
Pil‐Sung Yang
,
+8 authors
B. Joung
Stroke
2018
Corpus ID: 53027912
Background and Purpose— Edoxaban is a direct oral factor Xa inhibitor with proven efficacy and safety among patients with atrial…
Expand
2018
2018
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial.
J. Douketis
,
S. Murphy
,
+6 authors
R. Giugliano
Thrombosis and haemostasis
2018
Corpus ID: 24138846
BACKGROUND Peri-operative management of anticoagulated patients with atrial fibrillation (AF) is challenging. To gain information…
Expand
2017
2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.
J. Steffel
,
C. Ruff
,
+7 authors
R. Giugliano
International journal of cardiology
2017
Corpus ID: 24353155
Highly Cited
2016
Highly Cited
2016
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
E. Bohula
,
R. Giugliano
,
+4 authors
E. Braunwald
Circulation
2016
Corpus ID: 10629522
Background: Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke…
Expand
Highly Cited
2016
Highly Cited
2016
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
Haiyan Xu
,
C. Ruff
,
+7 authors
E. Braunwald
Journal of the American Heart Association
2016
Corpus ID: 30301718
Background We studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent…
Expand
Highly Cited
2016
Highly Cited
2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial…
N. Rost
,
R. Giugliano
,
+10 authors
E. Braunwald
Stroke
2016
Corpus ID: 3696811
Background and Purpose— Patients with atrial fibrillation and previous ischemic stroke (IS)/transient ischemic attack (TIA) are…
Expand
Highly Cited
2016
Highly Cited
2016
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF‐TIMI 48
G. Magnani
,
R. Giugliano
,
+9 authors
E. Braunwald
European journal of heart failure
2016
Corpus ID: 21072143
In the ENGAGE AF‐TIMI 48 trial, edoxaban, a factor Xa inhibitor, was not found to be inferior to warfarin for the prevention of…
Expand
2011
2011
Hospital de día de enfermedades respiratorias: impacto sobre la tasa de ingresos hospitalarios por exacerbaciones de la enfermedad pulmonar obstructiva crónica
Luis Fernando Sanchez Mendez
,
Concepción Montón Soler
,
M. B. Mañas
,
J. Salas
,
Xavier Pomares Amigó
,
U. A. Larracoechea
2011
Corpus ID: 196377762
2010
2010
Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease
J. Moltó
,
J. Sanz-Moreno
,
+4 authors
B. Clotet
Antimicrobial Agents and Chemotherapy
2010
Corpus ID: 23273110
ABSTRACT Little is known about raltegravir removal by hemodialysis in patients with end-stage renal disease (ESRD). We therefore…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE